Literature DB >> 10942959

New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999.

J M Reichert1.   

Abstract

The Tufts Center for the Study of Drug Development has collected data on the clinical and approval phases of the 26 new biopharmaceuticals approved by the US Food and Drug Administration between 1980 and 1999. Here, the data for biopharmaceuticals approved between 1995 and 1999 are presented grouped by product category, review status, orphan-drug designation and therapeutic indication, and the mean phase lengths are compared. They are also compared with the data for approvals during the periods 1982-1989, 1990-1994 and 1996-1998.

Mesh:

Substances:

Year:  2000        PMID: 10942959     DOI: 10.1016/s0167-7799(00)01473-6

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  2 in total

1.  Trends in US approvals: new biopharmaceuticals and vaccines.

Authors:  Janice M Reichert
Journal:  Trends Biotechnol       Date:  2006-06-06       Impact factor: 19.536

2.  Production and characterization of specific monoclonal antibodies binding the Plasmodium falciparum diagnostic biomarker, histidine-rich protein 2.

Authors:  Chiuan Herng Leow; Martina Jones; Qin Cheng; Stephen Mahler; James McCarthy
Journal:  Malar J       Date:  2014-07-18       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.